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Abstract 
 Polo-like kinase 3 (Plk3) is a member of a conserved family of serine/threonine kinases 
that primarily regulate cell cycle progression and mitotic events. In response to ionizing radiation, 
Plk3 facilitates the activation of G1/S checkpoint arrest. Further, published data from our lab 
suggested that Plk3 may be capable of activating G1/S checkpoint arrest independent of p53 
signaling. The tumor suppressor protein p53 is the central hub of DNA damage response signaling 
and the most frequently deleted or mutated gene in cancers. A Plk3-dependent, p53-independent 
mechanism for G1/S checkpoint arrest could partially compensate for the loss of p53 function. 
Therefore, in our first project, we investigated the hypothesis that the combined loss of p53 and 
Plk3 would be synthetic lethal with cell death resulting from the abolishment of the G1/S 
checkpoint and the accumulation of unrepaired DNA damage. However, our experimental results 
did not support our hypothesis and we decided to shift to a new project.  The Plk literature also 
suggests that Plk3 may have additional roles associated with normal cell function. Here, mouse 
embryonic fibroblasts generated from Plk3 knockout or wildtype mice were compared, to identify 
alternative functions for Plk3 in addition to its canonical role. Specifically, Plk3 has been reported 
to associate with key proteins involved in cytoskeletal organization; co-localizing with f-actin and 
directly phosphorylating β-tubulin. These and other data suggested a role for Plk3 in regulation of 
the cytoskeleton and cell morphology. To this end, given the importance of dynamic cytoskeletal 
rearrangement to cell motility, we analyzed whether Plk3 is involved in cell migration, attachment 
and/or invasion using Plk3 knockout mouse embryonic fibroblasts.  
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1.1: General Background on Polo-like Kinases  
In 1988, Sunkel and Glover described a mitotic mutant of D. melanogaster, they termed 
polo, which displayed mitotic abnormalities.  Mutation of the polo locus in fruit flies led to 
abnormal spindle poles and misalignment of chromosomes (1). Several years later, the same group 
demonstrated that the polo locus encoded a serine/threonine protein kinase, also termed polo, 
which was required for proper cell division (2). In humans, the polo equivalent, termed Polo-like 
kinase 1 (Plk1), was first described in 1994 by the laboratory of Klaus Strebhardt (3). Since then, 
the polo-like kinase family has expanded to include four additional members in humans that would 
come to be designated Plk2 through Plk5 (4-7). 
Evolutionarily, orthologues of Plk1 have since been identified in most eukaryotes, with the 
notable exception of plants and some protists. Plk4 is the second oldest Plk: found in some fungi 
and protists as well as all animals. Plk2 is present in some but not all animals with bilateral 
symmetry, while only in vertebrates did gene duplication of Plk2 lead to the generation of Plk3. 
Finally, a subsequent duplication of Plk3 appears to have produced Plk5, which has thus far been 
found only in Xenopus and mammals (Fig. 1) (8). 
 
 
Figure 1: Evolutionary expansion of polo-like kinases.  
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Genetic ablation of Plk1 in mice results in embryonic lethality, with embryos failing to 
divide past the 8 cell stage (9). Complete loss of Plk4 is also embryonic lethal in mice due to failed 
gastrulation at around embryonic day 7.5 (10).  Plk2 knockout mice are reported to be viable and 
fertile, but some pups display slightly retarded growth rates in utero (11). Likewise, Plk3 knockout 
mice are also viable with no apparent disease phenotype (12), although a different group has 
reported that Plk3 knockout mice may have an increased incidence of tumors compared to their 
wildtype counterparts (13). One interesting possibility is that the absence of a more severe 
phenotype in both Plk2-null mice and Plk3-null mice is the result of functional redundancy 
between Plk2 and Plk3. The consequences of Plk5 ablation in mice remain undetermined. From 
an evolutionary perspective, it is interesting that rodent Plk5 is expressed and translated into a full-
length, enzymatically active protein but PLK5 in humans and the great apes contains a pre-mature 
stop codon within exon 6, followed by an internal translation initiation site, leading to expression 
of a truncated protein without a functionally active kinase domain (7).  This finding is of interest 
because it suggests that Plk5, most closely related to Plk2 and Plk3, may be capable of partially 
compensating for the loss of either or both of these genes in mice, but not in humans. 
Although Plks display a range of functions, they have primarily been studied as regulators 
of cell division and mitosis. Plk1 drives cells through the G2/M transition and into mitosis by 
phosphorylating members of the cyclin/cdk pathway (14-16). During prophase, Plk1 primarily 
localizes at the centrosome and regulates proteins involved in centrosome maturation (17,18). By 
metaphase, Plk1 is enriched at the kinetochore where it functions to ensure the proper alignment 
of chromosomes and that sister chromatids separate entirely (19). Lastly, Plk1 localizes to the 
central spindle and midbody during anaphase and telophase to facilitate cleavage furrow formation 
and ensure completion of cytokinesis (20,21). 
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Perhaps unsurprisingly, Plk2 and Plk3 have also been shown to participate in the regulation 
of the cell cycle.  While Plk3 may potentially facilitate entry of cells into S-phase, a major role of 
both Plk2 and Plk3 appears, in contradistinction to Plk1, to be activation of cell cycle checkpoints 
in response to cellular stress or errors during mitosis (12,22-26). In order to participate in all of 
these events, the localization of Plks must be dynamically regulated. This regulation is mediated 
through the presence of a characteristic phosphopeptide-binding domain termed a polo-box 
domain (PBD) (27,28). 
The clinical significance of Plks is brought into focus by the cancers and neuropathies 
associated with Plk dysfunction (29-32). Plk1 is an oncogene. Overexpression of Plk1, which is 
reported in many types of cancer, is sufficient to transform NIH3T3 cells (33). Further, high levels 
of Plk1 expression have been correlated with poor clinical outcomes in several human cancer 
subtypes (34-36). In the brain, there is evidence that overexpression of Plk1 may kill neurons (37).  
 In contrast to the oncogenic properties of Plk1, both Plk2 and Plk3 display characteristics 
of tumor suppressors. For example, the Plk2 gene is epigenetically silenced in many B-cell 
lymphomas and in a subset of ovarian cancers, and loss of Plk2 expression correlates with poor 
outcomes (38-41). Likewise, Plk3 is down-regulated in cancers of the lung, liver cancers, and in 
cancers of the head and neck (42-44). In contrast to Plk1, expression of Plk2 and Plk3 is suggested 
to have important roles in healthy brain function (37,45,46). However, both kinases have also been 
linked to amyloid-formation and the development of Parkinson’s disease and dementias (32,47). 
1.2: The Structure of Polo-like Kinases   
Plks possess an N-terminal kinase domain connected via a linker region to a C-terminal 
Polo-Box Domain (PBD) (27). The PBD is a targeting domain through which Plks bind to specific 
phosphoserine and phosphothreonine motifs on target proteins (48). The PBD of each Plk, except 
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Plk4, contains two copies of a uniquely conserved motif termed a polo-box (PB). Until recently, 
Plk4 was believed, based on sequence analysis, to possess only a single functional PB (5,49). 
However, subsequent structural analysis revealed the presence of two additional polo-box domains 
that despite sequence variation maintain PBD function (50).  
The crystal structure of the PBD of Plk1 has been solved and provides insight into how 
Plk1 binds to substrate proteins. The two polo-box motifs form a “pincer” that folds together to 
secure the target phosphopeptide (28). A proteomic screen for the consensus binding motif 
recognized by the Plk1 PBD demonstrated a strong selective pressure for Serine at the n-1 position. 
The presence of a proline residue at the n+1 also favored Plk1 binding but was not required. 
Interestingly, the Plk1 PBD binds with 7-fold increased affinity to the target motif when the motif 
contains phosphothreonine instead of phosphoserine. Thus, the solved consensus target 
recognition site is Ser-pSer/pThr-Pro/X, where X is any amino acid (28). Notably, the finding that 
Plks selectively bind to phosphorylated motifs places Plks downstream of other kinase signaling, 
since a potential Plk substrate or a neighboring protein within a complex would frequently need to 
be phosphorylated to create a Plk docking site. Additionally, although Plk2 and Plk3 also contain 
conserved PB motifs, it now appears that the PBD of Plk2 and Plk3 may not share binding sites 
with the PBD of Plk1. As in another study, when the PBD of Plk1 was selectively replaced with 
the PBD of either Plk2 or Plk3, the resulting proteins demonstrated at least a 100 fold reduction in 
binding affinity compared to Plk1 for the consensus Plk1 PBD-targeted phosphopeptide motif (51).  
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Figure 2: Schematic of the five polo-like kinases in humans. The kinase domain (yellow) is 
situated near the N-terminus, except for in Plk5, which does not possess a functional kinase 
domain. The polo-box domain (blue + red) is located near the C-terminus and contains two or three 
polo-box motif (blue).  
 
Human Plks, except Plk5, contain a kinase domain near the N-terminus. The consensus Plk 
substrate differs substantially from that of the majority of cellular kinases which are either 
basophilic or which have a proline residue immediately adjacent to the phosphorylated residue.  In 
contrast, the Plks are acidophilic and phosphorylate serine/threonine residues located near 
glutamic acid or aspartatic acid (52). The recognition of phosphorylation sites on substrates by the 
presence of nearby acidic residues is an attribute Plks share with less than 5% of cellular kinases, 
most notably, with the casein kinase (CK) family. However, neither CK1 nor CK2 has been shown 
to share in vivo substrates with Plks (52). The consensus Plk1 phosphorylation site is 
(E/D)(E/D)(S/T) with preference given to acidophilic residues at n-2 and n-1 (53).  Additionally, 
Plk1 demonstrates negative selection for potential target sequences in which a proline resides in 
the n+1 position, which means that Plk1 phosphorylation sites are unlikely to overlap with those 
of most cellular kinases. That the kinase domains of Plks are evolutionarily isolated to such an 
extent suggests it may be difficult for other cellular kinase to directly compensate for the loss of 
Plks. As Plk1 is required for mitosis, its comparatively unique mechanism of substrate recognition 
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may have evolved to isolate Plk1 target residues and thereby prevent inadvertent activation of Plk1 
dependent mitotic events. 
Salvi et al. also demonstrated that the kinase domains of Plk2 and Plk3 share a significant 
number of substrates. The consensus sequence for Plk3 phosphorylation is predicted to be 
E(D/E)XS/TX(D/E) with a preference for acidophilic residues at the n-3, n-2, and n+2 positions 
and with X representing any amino acid. In this study, the number of known Plk2 phosphorylation 
targets was not sufficient for analysis; however, numerous new targets for the two kinases were 
determined.  Subsequent analysis of both the known and newly identified phosphorylation targets 
showed that Plk2 and Plk3 share a significant percentage of substrates, strongly suggesting that 
both kinases recognize similar acidophilic sequences and share some degree of functional 
redundancy (53). The kinase domains of Plk2 and Plk3 are also redox-regulated. The presence of 
DTT, a reducing agent, increased the phosphorylation of α-casein by up to six fold in vitro. Further, 
the presence of conserved cysteines within the ATP binding clefts and activation loops of Plk1, 
Plk2, and Plk3 capable of forming disulfide bridges also suggests redox regulation of kinase 
activity in Plks. Lastly, the same study demonstrated that Plk2 and Plk3 unlike the acidophilic 
casein kinases are incapable of using GTP in phosphorylation reactions, which could provide an 
important tool for distinguishing substrates between the two kinase families (54).  
The intracellular localization of Plk1 is dynamic and depends upon cell cycle phase. 
Translocation of Plk1 to the nucleus is facilitated by a bipartite nuclear translocation signal at 
residues 134-136 and 143-146, as determined by overexpression of an NLS-disrupted mutant (55). 
Expression of this mutant Plk1 prevented nuclear translocation and led to G2 checkpoint arrest 
(55). All other members of the Plk family also possess putative NLS sequences, but their 
functionality requires experimental validation. 
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The kinase activity of Plk1 appears to be regulated by intramolecular interactions. 
Flexibility in the linker region connecting the kinase domain and PBD allows the PBD to fold back 
and bind the kinase domain like a clamp. This conformation is inhibitory of Plk1 kinase activity 
and can be relieved in response to phosphorylation on threonine 210 by Aurora A kinase. 
Importantly, this threonine residue is conserved in Plk2, Plk3 and Plk4 suggesting a shared 
mechanism for self-inhibition (56).   
1.3: Polo-like Kinases and Cell Cycle Regulation 
 Proper execution of the cell cycle requires highly coordinated regulation within a core 
group of cell cycle proteins. The Plks participate in nearly every process within these regulatory 
signaling networks with roles in the G1/S transition, the G2/M transition, the activation of 
checkpoints, and completion of cytokinesis (21,57-59).  
One study suggested that Plk3 is required for entry of cells into S-phase (60). This finding 
is consistent with the increase of Plk3 observed prior to the G1/S transition (61). Knockdown of 
Plk3 with shRNA halted cell division at G1/S boundary. The arrested cells were subsequently 
shown to have reduced Cyclin protein levels, the expression of which is necessary for cells to 
transition into S-phase. The study further showed that knockdown of Cdc25A, both a Plk3 
substrate and direct regulator of Cyclin E stability, mimicked the phenotype associated with loss 
of Plk3. The authors suggest that Plk regulates entry into S-phase indirectly through Cdc25A 
stabilization of Cyclin E (60). 
The above study, however, appears in conflict with subsequent work demonstrating that Plk3 
participates in the activation of G1/S cell cycle arrest in response to ionizing radiation. Plk3-
deficient thymocytes displayed defective G1/S checkpoint activation and an increased abundance 
of Cdc25A (12). In order to induce G1/S checkpoint arrest, Plk3 was shown to phosphorylate 
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Cdc25A on both Ser513 and Ser519 to stimulate its ubiquitin-mediated degradation. Cdc25A was 
subsequently no longer available to activate the Cdk2/Cyclin E complex, causing cells to arrest 
prior to entry into S-phase.  Plk3 also participates in G2/M checkpoint arrest. Plk3 has been shown 
to phosphorylate Chk2 on serine 62 and serine 73. This acts as a priming event for phosphorylation 
of Chk2 by ataxia-telangiectasia mutated (ATM) and contributes to the full activation of Chk2 
kinase activity. Once fully activated, Chk2 phosphorylates Cdc25c leading to its ubiquitin-
mediated degradation and the initiation of G2/M checkpoint arrest (25).  
In the absence of challenge, Plk2 protein levels peak between late G1 and early S phase, 
but Plk2 is not required for normal progression though the cell cycle (11). This population of Plk2 
is thought to play a nonessential role in centriole duplication, but it also might be capable of 
promoting intra-S-phase arrest in response to replicative stress (26,62). In lung cancer cells treated 
with the DNA polymerase inhibitor, aphidicolin, Plk2 was shown to interact with both Chk1 and 
p53, two important initiators of cell cycle arrest following replicative stress. The same cells 
showed a decrease in the levels of pSer317-Chk1, an activating ATR phosphorylation, following 
shRNA-mediated knockdown of Plk2 (26), suggesting that inhibition of Plk2 impairs the DNA 
damage response. However, since, the study did not show an actual defect in S-phase arrest in cells 
depleted for Plk2, these results await further validation.  
The kinase activity of Plk1 is important for progression of cells from the G2-phase into 
mitosis. Plk1 promotes mitosis by facilitating its nuclear translocation and its activation of the 
Cyclin B/Cdk1 complex. The Cyclin B/Cdk1 complex is kept inactive in the cytoplasm via 
phosphorylation by the Wee1 and Myt1 kinases until late G2, at which point Plk1 directly 
phosphorylates and inactivates the Wee1 kinase to prevent the inhibitory phosphorylation of the 
Cyclin B/Cdk1 complex (63). Additionally, Plk1 phosphorylates Cdc25C phosphatase on its 
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nuclear export signal allowing Cdc25C to exit from the nucleus. Once in the cytoplasm, the 
Cdc25C phosphatase removes the inhibitory phosphate groups added to Cdk1 by Wee1 and Myt1. 
The now active Cyclin B/Cdk1 complex can translocate into the nucleus to drive mitotic entry 
(15,16). 
In contrast to Plk1, Plk3 activates the G2/M checkpoint in response to DNA-damage. Plk3 
phosphorylates Chk2 kinase on Ser62 and Ser73, which serves as a priming event for ATM 
phosphorylation of Chk2. Phosphorylation by ATM fully activates Chk2 kinase activity which 
then phosphorylates Cdc25C on Ser216. Cdc25C phosphorylation allows 14-3-3 to mediate its 
export from the nucleus. Cytoplasmic Cdc25C removes the activating phosphate from Cdk1 and 
initiate G2/M arrest (23).  The kinase activity of Plk3 is itself indirectly dependent on ATM.  When 
an ATM-deficient cell line was exposed to a DNA-damaging agent, Plk3 activity was unaffected 
(22). 
After DNA-damage has been repaired, a Plk1-dependent mechanism is necessary for the 
prompt reactivation of the cell cycle following G2/M checkpoint arrest (64-66). For cells to recover 
from such arrest, DNA damage-induced repair pathways dependent on ATM and ATR must be 
silenced, since inactivation of these pathways is required for the reactivation of Cyclin B/Cdk1. 
Aurora A kinase initiates this process by phosphorylating Plk1 on Thr210, relieving intramolecular 
inhibition within Plk1, thereby stimulating its kinase activity (56). Phosphorylated Plk1 is recruited 
to a complex containing P53 Binding Protein 1 (53BP1), ATM, and Chk2, where it is in proximity 
to Chk2. Plk1 phosphorylates and inactivates Chk2, thereby silencing downstream ATM signaling 
and allowing for reactivation of the cell cycle (66). In addition, Plk1 phosphorylates Claspin, an 
adaptor protein necessary for ATR to activate Chk1. Phosphorylation by Plk1 results in the 
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ubiquitin-mediated degradation of Claspin, which also is necessary for the proper reactivation of 
the cell cycle (65). 
Full execution of cytokinesis requires Plk1 activity, as demonstrated by Plk1 knockdown 
experiments using Plk1-specific inhibitors (20,67). When Plk1 inhibitors are added during late 
anaphase, polyploidy ensues due to a failure to complete cytokinesis. The observed polyploidy 
appears to be due to the failure of Plk1 to localize to the spindle midzone, a bundle of antiparallel 
microtubule arrays located between the two sets of sister chromosomes, during the late stages of 
mitosis (20). At the midzone, Plk1 associates with the proteins PRC1 and MKLP2, before 
phosphorylating the Rho GTPase-activating protein HsCYK4 (67). Phosphorylation of HsCYK4 
by Plk1 creates a docking site for the Rho GTP exchange factor ECT2, and this interaction is 
crucial for the assembly of an actomyosin ring at the cell cortex. Constriction of the actomyosin 
ring is required for cleavage furrow formation to create two individual daughter cells. In the 
absence of Plk1 the actomyosin ring can fail to form and/or restrict properly, thereby leaving two 
conjoined daughter cells (67). 
1.4: Polo-like Kinases and Mitosis 
The Plks are recruited to defined sub-cellular localizations at specific stages to ensure the 
proper execution of mitosis. Initially, Plk1 associates with centrosomes immediately prior to and 
during prophase and is required for the formation of bipolar spindles. In the absence of Plk1, cells 
fail to recruit γ-tubulin to the centrosome (68). Absent γ-tubulin, the microtubule nucleation 
integral for centrosome maturation does not occur. The activity of Plk1 at the centrosome is not 
fully understood; however, Plk1 is known to regulate several centrosomal proteins via 
phosphorylation (18,19). Ninein-like protein (Nlp), for example, is a promoter of microtubule 
nucleation at the centrosome that is phosphorylated by Plk1 and displaced from the centrosome to 
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prevent excess γ-tubulin accumulation (18). Similarly, Kizuma is a centrosomal protein that is 
phosphorylated by Plk1, but its exact function remains unclear. However, when Kizuna is depleted 
or unable to be phosphorylated by Plk1 the centrosome becomes unstable. Furthermore, these 
unstable centrosomes appear to be fragmented by the mechanical forces generated during 
chromosome alignment (19). 
Chromosome alignment during mitosis appears to require Plk1 activity via interaction with 
and phosphorylation of Topoisomerase IIα (Topo IIα). Topo IIα is required for chromosome 
condensation and separation of mitotic chromosomes. Phosphorylation of Topo IIα at S1337 and 
S1534 by Plk1 significantly increases its enzymatic activity. Furthermore, ectopic expression of a 
Topo IIα mutant that is unable be phosphorylated by Plk1 leads to the accumulation of catenated 
DNA, activation of the ATM-dependent DNA-damage response, and S-phase checkpoint arrest 
(69). 
The separation of sister chromatids in anaphase requires destabilization of Cohesin protein 
complex. Plk1 is responsible for completely removing most of cohesin from chromosome arms 
during prophase (70,71).  This is achieved by Plk1 phosphorylation of the SA2 subunit of cohesin 
leading to the disassociation of cohesin from the chromosome. Later, as the cell transitions from 
metaphase to anaphase, the remaining cohesin located at the centrosome is cleaved by a protein 
called separase (71). Plk1 phosphorylates the cohesin subunit Scc1, to enhance its cleavage by 
separase. In cells deficient for Plk1, the separation of chromosomes by separase only occurs after 
cells override the spindle assembly checkpoint (70).     
As part of metaphase, Plk1 also participates in activation of the anaphase-promoting 
complex/cyclosome (APC/C), to promote metaphase to anaphase transition, once chromosomes 
are properly attached to the spindle. While Plk1 may directly activate APC/C by phosphorylation 
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of several of its subunits, it may not be essential since Plk1 knockdown only partially reduces 
phosphorylation, perhaps as a consequence of redundancy with other kinases. Conversely, APC/C 
can also regulate Plk1 activity, producing a negative feedback loop. Following mitotic exit, Plk1 
is subject to ubiquitin-mediated degradation via APC/cyclosome, which targets a destruction-box 
motif located within the linker region of Plk1, resulting in the ubiquitin-mediated degradation of 
Plk1 (72). 
In contrast to Plk1, there appears to be a limited role for Plk2 within mitosis. Plk2 localizes 
to the centrosome where it may participate in centriole duplication (62). Exogenous expression in 
U2OS osteosarcoma cells of a Plk2 kinase-dead mutant or knockdown of Plk2 with a shRNAs 
interferes with centriole duplication and leads to abnormalities in centriole numbers compared to 
controls. The presence of Plk2, however, is not essential for carrying out centriole duplication, as 
ablation of Plk2 does not cause cell death.  
Like Plk2, the involvement of Plk3 in the regulation of mitotic events is also largely 
unexplored. Plk3 associates with the centrosome, as detected by co-localization of Plk3 and γ-
tubulin (22). In addition, Plk3 is also found at the midbody during telophase. This population of 
Plk3 has been suggested to be important for the completion of cytokinesis, as T47D breast cancer 
cells devoid of Plk3 frequently fail to divide resulting in a significant proportion of multinucleated 
cells (73). 
1.5: Polo-like Kinases and Disease  
Much of the research on Plks has been focused on the role of Plk1 in cancer. This interest 
was sparked by the initial observation that ectopic expression of Plk1 is sufficient to cause 
oncogenic transformation in NIH3T3 cells and to induce tumor growth in nude mice (33). The 
literature now strongly supports that Plk1 has oncogenic potential. The promotion of oncogenesis 
 14 
 
requires a shift away from cellular homeostasis and towards proliferation. Consistent with its 
oncogenic properties in cultured cells, Plk1 overexpression has been recorded in many different 
types of cancer, including cancers of the head and neck, stomach, breast, and ovaries (30).  High 
levels of Plk1 expression are also associated with poor prognosis and correlate with the metastatic 
potential of cancers. Increased Plk1 activity accelerates cell progression into and through M phase, 
driving cancer cells to continuously divide. Because of its function in aligning and sorting 
chromosomes, Plk1 is also likely to play a role in the occurrence of aneuploidy and/or polyploidy 
in cancers (29,30,36).   
Although considerably less is known about the role of Plk2 in cancer, it is a potential tumor 
suppressor as evidenced by its expression in primary B lymphocytes and its high frequency of 
epigenetic silencing in B-cell lymphomas. The aberrant cytosine methylation at the 5’ end of Plk2 
gene can be reversed with demethylation agents or by ectopic expression of Plk2 in B-cell 
malignancies resulting in the induction of apoptosis, providing selective pressure to keep Plk2 
function silenced in these cancers (40,74). 
Epigenetic silencing of Plk2 has also been reported in chemotherapy resistant endothelial 
ovarian cancers (EOC). As in B-cell lymphomas, Plk2 is down-regulated by methylation in 
Paclitaxel-resistant EOC cell lines at the 5’ end of the Plk2 gene (41). Furthermore, the reduction 
in Plk2 expression correlated with the level of drug resistance.  Interestingly, the expression of 
Plk1, Plk3 and Plk4 were unchanged as a consequence of resistance.  Clinically, Plk2 methylation 
levels in EOC tumors correlated with the likelihood of relapse during post-operative carboplatin 
and paclitaxel treatment. Patients with methylated Plk2 also showed overall reduced survival (41).  
While this mechanism of Plk2 suppression is not uncommon in B-cell lymphomas and ovarian 
cancers, inactivating mutations of Plk2 are not known to occur in other cancer types. 
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Plk3 also has tumor suppressive characteristics.  There is, for example, an inverse 
correlation between Plk3 expression and several cancers types, such as lung carcinomas and 
tumors of the head and neck (42,43).  Interestingly, although polymorphisms were detected in lung 
cancers, inactivating mutations were not found, suggesting that the down-regulation of Plk3 in 
lung cancer is accomplished by an alternative mechanism (43).  Given that Plk2 is epigenetically 
regulated in B-cell malignancies, it would be of interest to determine whether epigenetic silencing 
of Plk3 occurs in these tumors.  The consequences, if any, of Plk3 down-regulation in these cancers 
are unclear. One group has reported that Plk3-null mice have an increased incidence of 
spontaneous tumors (13).  In contrast, a second group, found no difference in tumor incidence 
between wildtype and Plk3-null mice, even though the location and extent of the Plk3 sequences 
removed were similar (12).  
The Plks appear to have a role in neural development and disease. Although expression of 
Plk1 is largely suppressed in the brains of healthy individuals, recent studies have implicated it in 
facilitating neuronal cell death in the brain.  In one study, in which the brains of hamsters were 
infected with the degenerative prion-disease scrapie, there was a significant increase in Plk1 
expression with a corresponding reduction in the level of Plk3 (37).  Furthermore, the extent of 
Plk1 increase and Plk3 decrease correlated with the stage of disease progression. Interestingly, the 
levels of the cell cycle drivers Cyclin B1 and PCNA were increased, although this was not directly 
linked to the increase in Plk1. Since no phospho-histone H3 staining was present, the neuronal 
cells were not undergoing mitosis. This is not surprising since initiation of mitosis in neurons is 
usually abortive and leads to M-phase arrest and the activation of apoptosis (75). One interpretation 
of these data is that Plk3 assists in the maintenance of cell cycle arrest in neurons and that 
inactivation of Plk3, in this case by prion-disease, leads to up-regulation of Plk1. Expression of 
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mitotic proteins may drive neurons into M-phase, thereby activating apoptotic cell death, which 
provides a potential mechanism to explain, in part, the neuronal degeneration associated with 
neurological diseases.    
In healthy brains, Plk2 and Plk3 appear to function in the remodeling of synapses following 
excitatory stimulus (45,46). Both Plk2 and Plk3 interact with the protein, spine-associated 
RapGAP (SPAR), which promotes the growth of dendritic spines by indirectly regulating actin 
dynamics (76). In cultured neurons, endogenous Plk2 localizes to the cell body and proximal 
dendrites following synaptic stimulation. The presence of Plk2 was shown to displace SPAR from 
dendrites and corresponded to a reduction in fully-formed dendritic spines and synapses (77).  
Calcium and integrin binding protein 1 (CIB1) is a calcium-modulated protein that is 
related to calcineurin and calmodulin and is active in cell-to-cell adhesion and intracellular calcium 
signaling. An interaction between CIB1 and Plk2, as well as CIB1 and Plk3 was first demonstrated 
in neuronal cells (45). The study investigated how kinases normally involved in cell cycle 
regulation and differentiation might function alternatively in the brain to control synaptic 
plasticity, which is the ability of neurons to modify the strength of the signal sent across synapses 
depending on the frequency of use. The expression of both Plk2 and Plk3 was significantly 
increased by stimuli that produce synaptic plasticity. Plk3 and Plk2 can also localize with CIB1 
following excitatory stimulus (45). It was subsequently shown that CIB1 interacts with Plk3, both 
in vitro and in vivo, at least in brain and some breast cancer cell lines. CIB1 interaction with Plk3 
is not dependent on the presence of calcium; however, CIB1 binding can inhibit Plk3 activity in a 
calcium-dependent manner (78). 
Dysregulation of Plk2 and Plk3 in the brain has been implicated in the pathophysiology of 
dementias and Parkinson’s disease. Both Plk2 and Plk3 can phosphorylate α-synuclein at Ser129 
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which causes the protein to form aggregates, a process known to be involved in the development 
of multiple neuropathies (47). Most studies, however, have predominantly focused on the role of 
Plk2 in this context because the level of Plk2 is significantly increased in brains of Alzheimer’s 
patients (32). Substitution of either of two residues known to be important for substrate 
recognition, Glu-126 or Glu-131, for alanine in α-synuclein abolishes Plk2 binding and 
phosphorylation of α-synuclein. Plk2 also co-localizes with Ser129-phosphorylated α-synuclein in 
mammalian cells, primary neurons, and in the brains of transgenic mice, thereby implicating Plk2 
in normal neuronal signaling (47). In vivo, genetic knockout of Plk2 in mice did not reduce the 
total level of α-synuclein but significantly reduced the levels of Ser129 phosphorylation. 
Comparatively, Plk3 knockout mice showed no decrease in the levels of either total or 
phosphorylated α-synuclein (79).  
  
  
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO:  
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
 
Cell culture 
Cell culture media and reagents were purchased from life technologies. Unless otherwise 
indicated, cell lines were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine (Fisher), 0.1 mM non-essential 
amino acids (Fisher), and 1% penicillin-streptomycin (Fisher) at 37°C in a humidified atmosphere 
containing 5% CO2. The p53-proficient and p53-deficient HCT116 cell lines were generously 
provided by the laboratory of Dr. Bert Vogelstein at the John Hopkins University.  
Mouse embryo fibroblasts were generated from E13.5 through E14.5 embryos. Pregnant 
mice were euthanized by exposure to concentrated CO2 followed by cervical dislocation to 
guarantee non-recovery. All efforts were made to minimize animal suffering. This work was 
conducted in strict accordance with the regulations established by Laboratory Animal Management 
Services at the University of Cincinnati. The protocol was approved by University of Cincinnati 
Institutional Animal Care and Use Committee (Protocol Number: 06-08-28-02). All MEFs used 
for experiments were 4th passage or earlier and all experiments were passage matched. Prior to 
experiments, MEFs were thawed from liquid nitrogen, plated and allowed to recover overnight. 
The following day cells were counted by hemocytometer and plated at equal cell number for 
experimentation.   
Genotyping and qPCR 
 Genomic DNA from mouse tail clips or ear punches was isolated using QIAamp DNA 
Mini Kit (Qiagen, Valencia, CA) and subjected to standard PCR. For genotyping Plk3, the primer 
sequences were 5’-AAACCACCTGTGTTGGTGATGTGC-3’ and 5’-
AGCTAGCTTGGCTGGACGTAAAC-3’ for the wildtype allele and 5’-
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TTTCCTGGAGCTCTGTAGCCGAAA-3’ and 5’-ACACCCATCTGTGCCATACACTCA-3’ 
for the insert in the Plk3 knockout mice. (IDT, San Jose, CA). For genotyping Tp53, the forward 
primer sequence was 5’-ACAGCGTGGTGGTACCTTTAT-3’ for both the wildtype and Tp53 
knockout allele. For the reverse primers, the sequences were 5’-TATACTCAGAGCCGGCCT-3’ 
for the wildtype allele and 5’-TCCTCGTGCTTTACGGTATC-3’ for the Tp53 knockout allele. 
For genotyping Plk2, the forward primer sequences were 5’-CTTGCTCGTACTCATCACGGCA-
3’ for the wildtype allele and 5’-CTGTGCTCGACGTTGTCACTG-3’ for the Plk2 knockout 
allele. The reverse primer sequence was 5’-AACCTAGTCACTTAGCAATGCCAGGT-3’ for 
both the wildtype and Plk2 knockout allele. For qPCR, total RNA was extracted from wildtype 
and Plk3-null MEFs with a commercially available magnetic mRNA isolation kit (Life 
technologies, Carlsbad, CA). One micrograms of total RNA was reverse transcribed using the 
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) Taqman probes against Plk3 and GAPDH 
(Life Technologies) were used to set-up qPCR reactions according to the Life Technologies’ 
suggested protocol. Target gene expression was measured as arbitrary units of RNA expression 
and repeated in triplicate. 
DNA-damage Assay (γH2AX staining) 
 Wildtype and Plk3, p53 double knockout MEFs grown on coverslips were exposured to 
5Gy ionizing radiation from an irradiator using a Cs137 source. After 1h cells were fixed for 30min 
with 4% paraformaldehyde, rinsed with PBS, permeablized for 10min with 1% Triton-X in PBS, 
and blocked for 1h with 10% Goat Serum in PBS. Coverslips were then immuno-stained with 
γH2AX antibody for 1h at room temperature, rinsed with PBS, stained with Alexa Fluor 488-
conjugated secondary antibody for 1h at room temperature in the dark. Nuclei we stained with 1 x 
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DAPI and the coverslips were mounted on microscope slides, imaged, and the average number of 
foci per cell was also assayed using ImageJ software. 
Cell Viability Assay 
Mouse Thymocytes were harvested from 6-8 week old animals. Mice were euthanized, 
sanitized with 70% EtOH, and dissected to remove the thymus. The thymus was rinsed with PBS, 
manually ground into thymocytes, and washed with red blood cell lysis buffer (Sigma). The 
thymocytes from p53, Plk3 double knockout and wildtype mice were separately counted, plated, 
and immediately exposed to IR (t =0h). At 24h and 48h post-IR exposure, the cells were stained 
with trypan blue, viable and dead thymocytes were counted, and the percent viability for each 
group was graphed. 
Lentivirus Production 
 PLKO.1-puro expression vectors containing shRNAs pre-validated against human Plk3 
were acquired from the Lenti-shRNA Library Core at Cincinnati Children’s Hospital and Medical 
Center. In a sterile cell culture hood, 1µl VSV-G, 2.5µl psPAX1, and 3µl pLKO.1 were incubated 
together for 30 minutes in serum-free media, prior to being added dropwise to 10cm plates of 
HEK293T cells at ~50% confluence in 5 ml of complete media. After 24 hours, the media was 
replaced. After another 24 hours, that media was harvested to collect the virus.  Transfection 
efficiency was estimated by using GFP-expressing pLKO.1 vector as a control.  Virus containing 
media was centrifuged to remove cellular debris and immediately used to transduce HCT116 cells.  
Lentivirus Transduction 
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 ShRNA lentivirus-containing media was mixed with an equal volume fresh media and 
added to HCT116 cells that were at 50-75% confluence. After 24h, the virus-containing media was 
replaced with fresh virus-free media and the cells were allowed to continue growing for an 
additional day. At roughly 48h post-transfection puromycin was added to the transduced cells for 
selection purposes. After two days of exposure to puromycin selection, the media was again 
replaced. Nearly 100 percent cell death was induced by puromycin treatment in the non-virally 
transduced HCT116 cells, indicating the cells were indeed sensitive to puromycin selection. In the 
transduced cultures, the surviving cells were keep under low-dose puromycin selection and 
considered stably transduced.  
Flow Cytometry 
 
HCT116 cells, with or without prior radiation exposure, were harvested at the various time points 
indicated. Harvested cells were washed with PBS, and suspended in 500 µl of PBS containing 
0.1% glucose to reduce clumping. Next, cells were fixed with 5 ml of cold 70% ethanol and 
stored for up to one week at 4°C, until samples from all time points were collected. Two hours 
prior to FACS analysis, cells were spun down, washed with PBS, spun down again, aspirated, 
and re-suspended in 300µl propidium iodine solution (BD bioscience) and put on ice for about 
30 minutes. Lastly, the cell suspensions were transferred to FACS tubes through filter caps to 
limit clumps. Experiments were run at Shriner’s Hospital for Children Flow Cytometry Core 
using a Coulter XL machine. The cell cycle distribution of 10,000 cells was analyzed for each 
cell type.  
Cytoskeleton Staining 
 MEFs were grown on coverslips prior to fixation with 4% paraformaldehyde in PBS for 
20 minutes. Cells were washed twice with PBS, permeablized and blocked with blocking buffer 
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(10% goat serum, 1% BSA, and 1% Triton X-100).  Cells were incubated with a primary antibody 
against β-tubulin at 1/500 (AbCam, Cambridge, UK) in blocking buffer for 1 hour at room 
temperature or overnight at 4°C. Alexa Fluor 546 conjugated secondary antibodies (Life 
Technologies) were diluted 1:2000 in buffer and added to cells for 1 h at room temperature in the 
dark. F-actin filaments were stained with Alexa Fluor 488-conjugated phalloidin (Life 
Technologies) using a 1:500 dilution for 1h at room temperature. DNA was stained with 1 x DAPI 
(Sigma-Aldrich) and coverslips were mounted onto slides using Fluromount G (Southern Biotech, 
Birmingham, AL). Cells were imaged by fluorescence microscopy (Zeiss) and images were 
recorded with Axiovision software. 
Multinucleation Assay  
 Coverslips were fixed and stained for β-tubulin and DAPI as described in the 
immunofluorescence section. Fifteen fields were imaged for both wildtype and Plk3-null MEFs. 
Mononucleated and multinucleated MEFs were manually scored. The percentage of 
multinucleated cells was calculated by dividing the total number of cells with 2 or more nuclei by 
the total number of cells counted. The experiment was repeated in duplicate and in each trial at 
least 500 cells were counted per cell type.   
Standard Scratch-wound Assay 
 5x104 cells wildtype and plk3-null MEFs were separately added to culture plates containing 
18 mm coverslips and allowed to grow to confluence overnight. The following morning, a single 
cell-coated coverslip was transported to the microscopy core at the Vontz Center for Molecular 
Studies at the University of Cincinnati and affixed to a live-imaging microscope at controlled 
temperature (37°C) and CO2 (5%) levels. Cells were scratched using a razor blade, an appropriate 
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field was located under the microscope and the accompany Axiovision software was set to record 
an image every 5 minutes until the completion of the experiment. The images were subsequently 
analyzed using ImageJ software. Individual cells were selected at random, tracked, and their 
locations marked every 15 minutes with a colored dot.  
IncuCyte Zoom Scratch-wound Assay 
The IncuCyte Zoom (Essen Bioscience, Ann Arbor, MI) an automated live-cell imager, 
was set-up and used according to the manufacturer’s instructions. Prior to migration experiments, 
the detection software was calibrated specifically for MEFs to ensure accurate distinction of cells 
from empty space. MEFs (2.5x104 cells/well) were plated into 96-well plates approximately 24 h 
prior to wounding. Cells were 95%-100% confluent at time of wounding. Scratch-wounds (~600 
μm) were made using the accompanying WoundMaker™ (Essen Bioscience). Plates were 
immediately placed into the IncuCyte Zoom and images were recorded every 15 minutes for 48 h. 
Experiments were conducted at 37°C and 5% CO2. The software incorporated into the IncuCyte 
Zoom was used to analyze the images and determine the rate of cell migration graphed as the 
percentage of wound confluence. Each data point graphed represents the mean of the 48 wells 
recorded per cell type.   
Woundless Migration Assay 
 Cells (2x106) were plated in 60mm cultures dishes printed with the vertically patterned 
Polylactic acid-linker-Polyethylene glycol (PLA-L-PEG) polymer. Cells were allowed to attach to 
the unprinted area and grown to confluence. Culture plates were exposed to low dose UV light to 
cleave the polymer from the cell attachment resistant PLA-L-PEG polymer to cell attachment 
permissive Poly-lactic acid. The cells were manually imaged every 4 h using a CCM camera 
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attached to a microscope (Nikon, TE-2000S) until the gap was closed. The fifteen fields were 
imaged per cell type and each image was individually analyzed at each time point using ImageJ to 
determine percent gap confluence. The resulting data set was graphed for each cell type. 
Attachment Assays 
 For assessing cell attachment to fibronectin and collagen, pre-coated plates were purchased 
from BD Biosciences (San Jose, CA). MEFs were counted and plated into individual wells of 12-
well plates at 3x105 cells/well. After 4 h, the media was aspirated, wells were gently washed with 
1 x PBS, and the attached cells were fixed with 4% paraformaldehyde. Cell attachment was 
measured by counting cells in three randomly selected fields per well. The counting was blinded 
such that the cell type in each well was not known until after the data were collected. The data 
were graphed as average number of cells attached per well. Each data point represents a single 
well and a minimum of 12 wells were counted for each cell type.  
Invasion Assay 
 For matrigel invasion assays, pre-coated matrigel plates were purchased from Millipore. 
MEFs were counted and plated at 1x106 cells/well into 0.1% serum-containing media in the upper 
chamber of the 12-well plates with 10% serum-containing media added to the bottom well to 
induce invasion. After 20 h, the media was aspirated and MEFs attached to the underside of the 
filter were fixed and stained using a Kwik-diff kit (Thermo Scientific, Waltham, MA). Filters were 
removed from the well with a scalpel and affixed to microscope slides using immersion oil. Five 
randomly selected fields were counted per well. The data were graphed as the average number of 
cells attached per well. A total of 12 wells were counted for each cell type. 
RNA sequencing 
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A commercially available magnetic mRNA isolation kit (Life Technologies) was used for the 
polyA RNA (including mRNA and polyA lncRNA) purification. A total of 1 µg total RNA was 
used as the input. An Apollo 324 system (WaferGen, Fremont, CA) was used and PrepX PolyA 
script for the automatic polyA RNA isolation. Using the same system, the isolated RNA was 
RNase III fragmented, adaptor-ligated, converted into cDNA with Superscript III reverse 
transcriptase (Life Technologies) and subjected to automatic purification using Agencourt  
AMPure XP beads (Beckman Coulter, Indianapolis, IN). Next, using the universal (SR) and index-
specific primer with a limited PCR cycle number (~13), sample-specific index was added to each 
ligated cDNA sample and the amplified library was enriched by AMPure XP bead purification 
with a final elution volume of 16 µl. To check the quality and yield of the purified library, one µl 
of library was analyzed by Bioanalyzer (Agilent, Santa Clara, CA) using DNA high sensitivity 
chip. To accurately quantify the library concentration for the clustering, the library was diluted 
1:104 in dilution buffer (10 mM Tris-HCl, pH 8.0 with 0.05% Tween 20), and qPCR measured by 
Kapa Library Quantification kit (Kapabiosystem Woburn, MA) using ABI's 9700HT real-time 
PCR system (Lifetech). The raw data (transcript counts) were transformed into RPKM tables by 
Dr. Mario Medvedovic’s lab in the Department of Environmental Health at UC for the purposes 
of comparative analysis and comparative gene expression levels were plotted using GraphPad 5 
statistics software.     
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CHAPTER THREE:  
Plk3, P53, and Synthetic Lethality  
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 Single target cancer therapies have mostly been disappointing due in part to tumor cell 
heterogeneity and also to compensatory pathways that allow some cells to escape the toxic effect 
of the therapeutic drug. Traditional therapeutics, such as those that affect processes like DNA 
replication that are fundamental to healthy cell survival are often accompanied by deleterious side 
effects. An alternative strategy is that of synthetic lethality, a concept first described by 
Dobzhansky about 70 years ago in crosses of Drosophila (80). Synthetic lethality refers to genetic 
interactions between two mutant genes, neither of which by itself is lethal, but which when 
combined confer a lethal phenotype. In principle, virtually every human tumor should be 
selectively susceptible to killing if a synthetic lethal gene is targeted. This rationale is based upon 
the accepted observation that most tumors have lost heterozygosity at one or more tumor 
suppressor loci. Targeting a gene or pathway that is synthetic lethal with the loss of tumor 
suppressor function should render those cells selectively vulnerable to killing. Only tumor cells, 
and not normal cells and tissues, will be affected by the therapeutic agent, whether it be a shRNA 
or a small molecule inhibitor. Since TP53 is the gene most frequently mutated in cancers, 
identifying a protein whose inhibition or loss is synthetic lethal with loss of p53 function would 
be of enormous therapeutic value. We hypothesized that Plk3 would be one such candidate since 
p53 and Plk3 are components of two different pathways that converge on cell cycle checkpoints. 
We hypothesized that if either p53 or Plk3 alone was lost, there would be no significant effect on 
the viability of cells.  However, if both were lost, the G1/S checkpoint would be compromised so 
that cells with damaged DNA would enter the S-phase and the damage would be exacerbated 
leading to diminished cell viability. 
 Cells with damaged DNA can arrest at the G1/S boundary to allow time for repair, thereby 
preventing accumulation of additional damage during DNA replication.  Both p53 and Plk3 
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function within converging DNA damage response pathways to activate the G1/S checkpoint. In 
response to DNA damage, p53 upregulates transcription of the kinase inhibitor p21CIP, which binds 
to CDK2/cyclin A and initiates G1/S checkpoint arrest (81-83). Likewise, Plk3 activates the G1/S 
checkpoint after DNA damage by direct phosphorylation of Cdc25a on two serine residues 
resulting in its degradation (12). Absent Cdc25a phosphatase activity the CDK2/cyclin A complex 
remains in an inactive state and cell cycle progression halts. These findings provided the basis of 
our project model; in the individual absence of either Plk3 or p53, cells would still be capable of 
initiating G1/S checkpoint arrest in response to DNA damage through the pathway mediated by 
the other protein. However, the combined loss of both p53 and Plk3 function would result in the 
inability of cells to activate G1/S checkpoint arrest. Our model further proposed that cells 
incapable of G1/S checkpoint activation would not be able to repair DNA damage prior to entry 
into S-phase leading to the accumulation of DNA damage during DNA replication, and ultimately 
cell death (Fig. 3).  
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Figure 3: Proposed Model for Plk3, p53 synthetic lethality. A.) G1/S checkpoint activation in 
the presence of both functionally p53 and Plk3. B.) G1/S checkpoint activation is proposed to be 
Plk3-dependent in the absence of p53. C.) G1/S checkpoint activation is proposed to be p53-
dependent in the absence of Plk3. D. G1/S checkpoint would fail to activate in the absence of both 
p53 and Plk3 leading to unregulated entry into S-phase, DNA damage accumulation, and eventual 
cell death. 
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 To test whether the combined loss of p53 and Plk3 functions is synthetic lethal, we have 
used a mouse model in which Tp53 and Plk3 expression were both genetically ablated. We had 
previously generated a Plk3 knockout mouse in which the promoter and first six exons of the Plk3 
gene were replaced by a neomycin-containing insert (12). The p53 knockout mice were generously 
provided by Dr. Gary Shull within the Department of Molecular Genetics, Biochemistry, and 
Microbiology at the University of Cincinnati. We first asked whether or not p53-/-, Plk3-/- mice 
were viable. The p53 knockout mice were crossed with the Plk3 knockout mice to generate p53+/-
, Plk3+/- doubly heterozygous animals which were sib-mated for determining the viability of the 
double null animals which should arise with a frequency of 0.062.  Of the 210 offspring produced, 
only six were p53-/-, Plk3-/- rather than the thirteen offspring predicted based on Mendelian 
inheritance.  The significance of the reduced number of p53-/-, Plk3-/- pups born gives a p-value 
of 0.02 (Fig. 4A). The significant difference between actual and expected values suggests that 
double knockout embryos have reduced viability. However, the number of p53-/-, Plk3+/+ mice was 
also significantly lower than predicted. These results raised the possibility that loss of p53 function 
alone was responsible for reduced viability of the embryos.  We conducted an additional set of 
crosses between p53+/-, Plk3+/- mice and p53+/-, Plk3-/- mice to investigate this possibility.  Again, 
the number of double-null animals born was significantly less than predicted, generating a single 
double-null mouse. However, in this case, the p53-/-, Plk3+/- pups were observed with the predicted 
frequency (Fig. 4B). Importantly, the surviving double-null animals did not display any 
morphological abnormalities. However, a number of the double-null mice did succumb to early-
onset cancers, which is a well described outcome in p53 knockout mice (84).   
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Figure 4:  Plk3, p53 double knockout mice are viable although born at a lower than predicted 
frequency.  A.) p53+/-, Plk3+/- x p53+/-, Plk3+/- mouse crosses showing the expected versus actual 
numbers of offspring generated for each genotype. B.) p53+/-, Plk3+/- x p53+/-, Plk3-/- mouse crosses 
showing the expected versus actual numbers of offspring generated for each genotype.  
 Given, the aforementioned role of both proteins in DNA damage response, we 
hypothesized that a portion of the double-null embryos may be succumbing to unrepaired DNA 
damage accumulated as part of the rapid cell division during embryonic growth. To this end, we 
generated Mouse Adult Fibroblasts (MAFs) from wildtype and double-null mice and stained for 
γH2AX as a marker for endogenous DNA damage. As expected, exposure to 3 Gy ionizing 
radiation resulted in the accumulation of significant DNA damage in the wildtype MAFs (Fig. 5A).  
Interestingly, the levels of γH2AX foci were equally elevated in both unirradiated and irradiated 
double-null MAFs. This observation suggests that the double-null MAFs may have reached the 
saturation limit of DNA damage through the accumulation of endogenous damage (Fig. 5B). 
Alternatively those with more damage detached from the surface and died. However, empirically, 
this damaged DNA did not appear to adversely affect the viability of the double null cells either 
prior to or after irradiation, as we did not see significant numbers of floating and/or rounded cells 
and the cells continued to proliferate.  As a tool for determining the validity of the hypothesis, this 
finding offered conflicting information because it suggested that cells in the double-null animals 
likely accumulated endogenous DNA damage, but that this damage did not reduce the viability of 
those cells.  
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Figure 5: Plk3, p53 double knockout MAFs possess high levels of endogenous DNA damage. 
A). Representative images of wildtype and Plk3, p53 double knockout MAFs stained for γH2AX, 
as a marker of DNA double-strand breaks with or without exposure to 5Gy ionizing radiation. B. 
Graph of the average number of γH2AX foci per cell for irradiated and non-irradiated wildtype 
and Plk3, p53 double knockout MAFs. 
 To further investigate if the combined loss of p53 and Plk3 sensitized cells to DNA damage, 
we exposed freshly harvested double-null mouse thymocytes to escalating dosages of ionizing 
radiation and assayed for cell viability using a trypan blue exclusion assay. The decision to switch 
cell types was made as it was thought that, compared to MAFs, thymocytes would show greater 
sensitivity to radiation exposure. Wildtype and double-null mouse thymocytes were isolated from 
6-8 week old mice and immediately irradiated with either 0,1,2,4, or 10 Gy. At 24 hours post 
irradiation the percentage of dead cells was measured. The data showed a clear difference between 
the genotypes (Fig. 6). The trend was the opposite of what the hypothesis predicted; the double-
null cells were protected from radiation-induced cell death compared to the wildtype cells (Fig 3). 
Again, we have not tested the single-null mutants, so we cannot be certain of the cause of the 
protective effect. However, the literature contains similar experiments in mouse thymocytes in 
which the sensitivity of cells with deleted p53 to radiation exposure was assayed. In these other 
cases, p53 loss of function alone is protective against radiation-induced cell death (85). This 
suggests the absence of p53 is likely responsible for radiation resistance, however, we obviously 
cannot be certain whether Plk3 deletion alters the phenotype without testing the single-null 
genotypes. These findings also called the basic hypothesis into question, because rather than 
sensitizing the double-null thymocytes to radiation exposure, there was a protective effect.  
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Figure 6: p53, Plk3 double-knockout thymocytes are protected from radiation-induced cell 
death. A.) Graph of the viability of Plk3, p53 double knockout thymocytes following exposure to 
0, 1, 2, 4, or 10 assayed by Trypan Blue exclusion assay. 
 At this point in the project, we decided to shift tactics and look at the consequences of 
combined loss of p53 and Plk3 in cancer cells. The rationale being that the endogenous DNA 
damage inherit to cancer cells may increase sensitivity to the loss of key cell cycle regulators. 
Additionally, a synthetic lethal relationship between p53 and Plk3 would ultimately need to exist 
in cancer cells for it to have clinical relevance. For this purpose, we acquired two colorectal 
carcinoma cell lines isogenic for p53; HCT116+/+ and HCT116-/- cell lines were generously 
provided by the Laboratory of Dr. Bert Vogelstein at John Hopkins University.   
 Based on our hypothesis, we predicted that G1/S checkpoint arrest would be absent in the 
p53-deficient, Plk3-knockdown cells after exposure to DNA-damage. Initially, we decided to 
determine the consequences of loss of p53 alone. In order to assay this question, we utilized 
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propidium iodine staining and flow cytometry to perform cell cycle analysis on IR-treated HCT116 
cells. We assayed the percentage of cells in each phase of the cell cycle following radiation doses 
of 0, 5, 10, and 15 Gray in HCT116+/+ and HCT116-/- cells. Interestingly, at 5Gy exposure, the 
percentage of cells in G0/G1 phase is nearly abrogated at the early time points (up to 8h). This 
reduction is observed in both the HCT116-/- cells and the HCT116+/+ cells (Fig. 7A). By the 16h 
time point, the percentage of HCT116+/+ cells in G0/G1 was again equivalent to untreated cells at 
approximately 30 percent. Interestingly, however, the percentage of cells in G0/G1 phase after 5 
Gy radiation failed to recover only in the HCT116-/- cells, at least by the 24h end point. 
Correspondingly, at early time points both cell lines cells saw an increase in the percentage of cells 
in both S phase (Fig. 7B) and G2/M phase (Fig. 7C), although at 16 and 24 hours post IR exposure, 
a greater percentage of the HCT116-/- cells remained in G2/M phase compared to the HCT116+/+ 
cells. These findings suggest that exposure to IR does not result in cell cycle arrest in G1/S phase 
regardless of the p53 status, at least in HCT116 cells. Instead, loss of p53 function may delay or 
impair the ability of HCT116 cells to recovery from low dose radiation and that, absent p53 
function, HCT116 cells stall at the G2/M checkpoint. 
 By contrast, both p53-proficient and p53-deficient HCT116 cells treated with 10 Gy or 15 
Gy ionizing radiation failed to re-enter cell the cycle. Instead, we again observed the near ablation 
of the G0/G1 phase, except it was sustained in both cell lines through the entirety of the 24h 
experiment (Fig. 7A).  Further, the cells that were initially in G0/G1 phase and S phase at the time 
of radiation exposure subsequently passed through S phase (Fig. 7B) and accumulated in G2/M 
phase (Fig. 7C). The cells that were initially in G2/M phase appeared to immediately arrest, as 
they are not observed re-entering G0/G1 phase. The cumulative effect of this response is that by 
24h, greater than 80 percent of HCT116+/+ and HCT116-/- cells accumulated in G2/M phase 
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compared to the roughly 20% of cells in G2/M phase in untreated samples. Importantly, while this 
experiment was only successfully run one time, meaning the findings are not conclusive, the result 
still informed our hypothesis, because it suggests that G1/G0 checkpoint arrest is absent in both 
the p53-proficient and p53-deficient HCT116 cells post IR radiation exposure and that only the 
G2/M checkpoint appears to be activated in response to DNA-damage in HCT116 cells.  
A. 
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Figure 7: HCT116 cells do not arrest at the G1/S checkpoint. A.) Flow cytometry data showing 
the percentage of p53-proficient or p53-deficient HCT116 cells in G0/1 phase after exposure to 0, 
5, 10, or 15 gray radiation. B.) Flow cytometry data showing the percentage of p53-proficient or 
p53-deficient HCT116 cells in S-phase after exposure to 0, 5, 10, or 15 gray radiation. C.) Flow 
cytometry data showing the percentage of p53-proficient or p53-deficient HCT116 cells in G2/M 
phase after exposure to 0, 5, 10, or 15 gray radiation.  
 The previous data set allowed us to choose a dosage of 5 Gy radiation for the next set of 
experiments; repeating the same cell cycle analysis with the addition of shRNA-meditated Plk3 
knockdown. At this point, we were aware that the hypothesis was not holding together, however, 
we had invested significant time and materials into developing Plk3 knockdown capabilities and 
we were still interested in whether the knockdown of Plk3 in HCT116 cells would alter their 
response to radiation exposure. To knock down Plk3, we utilized a lentivirus-based system. This 
system offered the advantages of target selectively and sustainable Plk3 knockdown compared to 
transient transfection with shRNA or the use of pharmacological inhibitors. Two unique Plk3 
shRNAs were selected from the shRNA consortium and obtained from the lentiviral core at 
Cincinnati Children’s Hospital and Medical Center. Despite repeated efforts, we were unable to 
detect endogenous Plk3 protein by western blot; either in MEFs or HCT116 cells. This limited our 
ability to determine the effectiveness of the shRNAs at reducing protein expression of Plk3. 
However, the lentiviral transduced cells survived selection with puromycin suggesting that the 
viral DNA was incorporated and being expressed. We also acknowledge that qPCR could have 
been used to at least determine the effectiveness of the shRNA against Plk3 mRNA expression, 
unfortunately, at the time that method was not considered.  
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 Using the HCT116 cell lines stably-transduced with each of the Plk3 shRNAs, we repeated 
the cell cycle analysis experiments to determine the combined effects of loss of p53 function and 
Plk3 knockdown on cell cycle progression. Consistent with the previous experiment, the data again 
showed a dramatic reduction in the percentage of cells in G0/G1 phase at 4h post radiation and the 
HCT116+/+ cells were reestablishing progression through the cell cycle by 24 hours (Fig. 8A).  
Recovery into G0/G1 phase again appeared delayed in the HCT116-/- cells and transduction with 
either Plk3 shRNA did not appear to alter this delay. 
 However, in the previous experiment there was no difference between the percentages of 
HCT116 cells in S phase 8 hours post radiation treatment (Fig. 7B). Contrary to that result, here, 
the HCT116-/- cells displayed a higher percentage of cells in S phase at 8h post-radiation exposure 
compared to HCT116+/+ cells in all four samples (Fig. 8B). These result suggest that HCT116-/- 
cells might first get delayed in S phase prior to accumulating at the G2/M checkpoint. Interestingly, 
these data suggest that knockdown of Plk3 may facilitate progression through S phase in the 
absence of p53. At 24h time point, the percentage of cells in S phase in the non-treated and non-
target shRNA HCT116-/- cells remained elevated at 24 post radiation treatment, but in cells 
transduced with either Plk3 shRNA, the percentage of cells in S-phase was roughly equivalent 
between the two cell types. Furthermore, in the Plk3 shRNA treated samples, this reduction of 
cells in S-phase in the HCT116-/- cells at 24 hours corresponded with an increase in the percentage 
of cells in G2/M phase (Fig. 8C). This finding remains unexplained and may warrant further 
investigation. Regardless, these finding significantly undermined our hypothesis. Regardless of 
the presence or absence of Plk3, the p53-deficient HCT116 cells both fail to activate G1/S 
checkpoint and remain arrested in G2/M phase, suggesting that loss of Plk3 is not required to 
disrupt G1/S checkpoint arrest. Nor does loss of Plk3 impair the ability of p53-deficient HCT116 
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cells to arrest at the G2/M checkpoint suggesting that dual inhibition of p53 and Plk3 is unlikely 
to result in the accumulation of DNA-damage through unregulated cell division. Combined with 
the resistance of double-null thymocytes to cell death following high dose radiation, we concluded 
that a Plk3, p53 synthetic lethal relationship did not exist and decided to move on. 
A. 
 
B. 
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C. 
 
Figure 8: p53-deficient HCT116 treated cells do not arrest at the G1/S checkpoint. A.) Flow 
cytometry data showing the percentage of p53-proficient or p53-deficient HCT116 cells with or 
without Plk3 shRNA treatment in G0/1 phase after exposure 5 gray radiation. B.) Flow cytometry 
data showing the percentage of p53-proficient or p53-deficient HCT116 cells with or without Plk3 
shRNA treatment in S phase after exposure 5 gray radiation. C.) Flow cytometry data showing the 
percentage of p53-proficient or p53-deficient HCT116 cells with or without Plk3 shRNA treatment 
in G2/M phase after exposure 5 gray radiation.   
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CHAPTER FOUR:  
Plk3, the Cytoskeleton, and Cell Motility  
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 Plk possesses cellular functions separate from its role in safeguarding cell cycle 
progression and cell division and these potential functions remain largely underexplored. Our 
study investigates one such novel Plk3 function suggested by the Plk literature and by a 
preliminary assay conducted in our lab. Previous publications have shown that Plk3 and the other 
Plks associate with cytoskeletal components and play a role in regulating cytoskeletal dynamics 
(17-19). The ability of cells to continuously reorganize the cytoskeleton is vital to the growth of 
cells and the proper execution of cell division. During mitosis, the centrosome serves as the 
command center for this continuous reorganization (20). All of the Plk family members except 
Plk5 are reported to localize to the centrosome during mitosis. Once present at the centrosome, 
they collectively function to ensure the proper duplication of centrioles, attachment of spindle 
poles, alignment of chromosomes, and separation of sister chromatids (21-24). The Plks help 
orchestrate these processes through phosphorylation of numerous centrosomal proteins including 
direct modification of cytoskeletal components (8,21). Many of the same structural proteins and 
signaling pathways involved in organization and coordination of the cytoskeleton during mitosis 
also regulate the structure and dynamics of the cytoskeleton in non-dividing cells (19,25,26).  
 More directly suggesting a possible role in cytoskeletal dynamics, Plk3 has been shown to 
phosphorylate β-tubulin although the physiological consequences of this phosphorylation are 
currently unknown (18). In addition, Plk3 has been demonstrated to co-localize with F-actin and 
its overexpression disrupts actin polymerization and results in cell rounding and eventually induces 
apoptosis (27). Another report suggests that Plk3 expression is induced in macrophages upon cell 
adhesion and shows that Plk3 interacts with the integrin regulator, Calcium and Integrin Binding 
Protein 1 (CIB1) (28).  Subsequently, CIB1 was reported to be a negative regulator of both Plk3 
kinase activity and cell migration (29,30). Lastly, Plk3-deficient MEFs displayed retarded and 
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non-directional migration compared to wildtype MEFs in a standard scratch-wound assay 
performed in our laboratory (Fig. 9). In aggregate, these findings suggest that Plk3 has a role in 
cytoskeletal regulation; however, causal relationships between Plk3 and cytoskeletal organization 
and cell motility have not been established. The intent of the work described here was to establish 
whether loss of Plk3 is sufficient to perturb cytoskeletal organization or interfere with cellular 
functions, such as maintenance of cell morphology, cell migration or cell adhesion. For this 
purpose, we again utilized MEFs from our Plk3-knockout mouse model in which the Plk3 gene 
has been inactivated by deletion of its promoter and first six exons (14).  
 
Figure 9: Knockout of Plk3 leads to reduced migration and non-directional movement in 
MEFs. Images from preliminary scratch wound assay showing the total migration of wildtype and 
Plk3 knockout MEFs into a wound after 24 hours. Each colored line indicates the migration pattern 
of a single cells over the time course of the assay.   
 The possibility of identifying a novel role for Plk3 in healthy cells was significant. 
Additionally, Plk3 has been shown to be down-regulated in several cancer subtypes suggesting a 
tumor suppressor function (16,31,32). Establishing whether or not Plk3 contributes to the 
 47 
 
regulation of cytoskeletal organization impacts our understanding of cell migration, invasion and 
motility and ultimately tumor cell metastasis. Lastly, and regardless of the outcome, our project 
would illuminate an understudied aspect of Plk3 biology and inform the direction of future studies. 
 Based on reports that Plk3 interacted with or co-localized with elements of the 
cytoskeleton, we asked whether the absence of Plk3 might have an overt effect on cytoskeletal 
organization.  We therefore stained Plk3-null MEFs and wildtype Plk3 MEFs with antibody to β-
tubulin to assess the gross microtubule architecture. Randomized images of the stained cells 
assessed in blinded fashion did not distinguish any differences in staining patterns between the 
isogenic MEFs (Fig. 10A, top panels). When cells were stained with phalloidin to examine F-actin 
architecture, there was also no apparent difference in F-actin organization (Fig. 10A, lower panels). 
Repeated attempts to stain the cells by immunofluorescence using antibody to Plk3 were 
unsuccessful since all of the anti-Plk3 commercially available antibodies tested lacked specificity 
and gave non-reproducible staining patterns. Lastly, Plk3 has been reported to play an important 
role in cytokinesis (23), a process in which regulation of the cytoskeleton is critical and which is 
required for proper division of a parent cell into two daughter cells. We therefore scored the cell 
populations for cells with multiple nuclei, an indicator of compromised cytokinesis.  MEFs were 
stained for β-tubulin and for the nuclear stain DAPI. The cells were imaged, and the number of 
interphase cells with two or more nuclei was manually counted as a marker of abnormal 
cytokinesis.  Rounded cells were not included in the count to eliminate cells actively undergoing 
cell division. As shown in figure 10B, there was no significant difference between the Plk3-null 
MEFs and wildtype MEFs in the percentage of cells with multiple nuclei. Collectively, our results 
showed there are no differences in cytoskeletal organization and morphology between Plk3-null 
and wildtype MEFs (Fig. 10B).  
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Figure 10. Loss of Plk3 does not visibly disrupt the arrangement of β-tubulin or F-actin in 
MEFs. A) Representative images showing immunofluorescent staining for β-tubulin (green, upper 
panels) and F-actin (red, lower panels). Cell nuclei were also stained with DAPI (blue). B) 
Quantification of interphase cells with two or more nuclei in wildtype and Plk3-deficient MEFs. 
 As another measure of cytoskeletal function, we asked whether Plk3 plays a role in cell 
migration. To this end, we assayed cell migration by three different methodologies. First, we 
sought to replicate the finding from the preliminary scratch wound assay. MEFs were plated onto 
glass coverslip and allowed to grow to confluence. The following day, the cell-coated coverslip 
was transported to the microscopy lab at the Vontz Imaging Core. The scratch-wound was made 
manually with a razorblade, immediately prior to the coverslip being inserted into the temperature 
and CO2
 controlled environment attached to the imaging microscope. Due to the fixed set-up of 
the live-cell imaging microscope, only a single coverslip could be assayed at time, meaning the 
Plk3 knockout MEF and wildtype MEF were imaged individually. The findings from this assay 
partially conflicted with the preliminary results. Unlike in the preliminary experiment, the Plk3 
knockout MEFs were capable of migrating directionally into the wound. However, again the rate 
of migration was reduced in the Plk3 knockout MEFs compared to the wildtype cells, as indicated 
 49 
 
by delayed wound closure and the use of ImageJ software to manually track the movement of 
individual cells over the time course of the experiment (Fig. 11).  
 
 Figure 11: Loss of PLK3 appears to reduce the rate of cell migration in MEFs. Images 
taken at 0, 8, 16 and 24 hours into the scratch wound assay showing the total migration of wildtype 
and Plk3 knockout MEFs into a wound. Again, each colored line indicates the migration pattern 
of a single cells over the time course of the assay.   
 Second, we used the IncuCyte Zoom, an automated live cell imager with high-throughput 
capabilities and built-in data analysis, as these and other features offered significant improvements 
compared to the use of a standard scratch wound assay. Cells were seeded into 96-well plates at 
equal density and allowed to grow to confluence overnight. The Essen Bioscience 
WoundMakerTM, an accessory for the IncuCyte ZOOM®, was utilized to create wounds of a 
standardized width. Cells were imaged every 15 minutes for at least 48 h and the percentage of 
wound confluence was analyzed at intermediate times and at the conclusion of the experiment.  By 
this assay, both wild-type and PLK3-null MEFs closed the wound at between 20 and 24 h (Fig. 
12A). These results are also graphed as the averages of 48 independent wells per cell type (Fig. 
12B). Based on these studies it appears that there is no difference in the rate of wound closing 
 50 
 
between wildtype and Plk3-null MEFs, suggesting that Plk3 does not participate in migration 
signaling. 
Since the previous assay is based on generating a wound, we employed a second approach 
which enables measurements of cell migration while avoiding the killing or damaging of cells at 
the edge of the wound during its creation. The method involves printing cell culture plates with a 
light-cleavable polymer that prevents cell attachment. By carefully controlling the positioning of 
the polymer it can be used to create patterned areas onto which the cells can be seeded. In this case 
the polymer was used to create strips of a defined width and MEFs were seeded into the area 
between strips. When the cell resistant polymer is exposed to low dosage UV light, the polymer is 
cleaved leaving behind poly-lactic acid; a material that is permissive for cell attachment, allowing 
the rate of cell migration into the previously restricted area to be observed. Briefly, cells were 
seeded into the patterned area for 24-48h prior to beginning the assay followed by exposure to low 
dose UV light (t = 0h). The cells were manually imaged every four hours, until the gap was closed. 
Both wildtype and Plk3-null cells migrated into the gap at a similar rate (Fig. 12C).  Multiple fields 
were imaged per experiment, the percentage confluence of each gap within the individual fields 
was quantified using ImageJ software, and the results were graphed as the average confluence of 
all fields at each time point.  Again, there was no significant difference in the rate of gap closure 
between the wildtype and Plk3-null MEFs (Fig. 12D). Thus, based on data from two very different 
methodologies, we conclude that absence of Plk3 does not impair fibroblast migration under the 
conditions used here. 
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Figure 12. Loss of Plk3 does not alter the rate of cell migration in MEFs. A) Representative 
images showing the migration of wildtype and Plk3-null MEFs using a standard scratch wound 
assay.  The wound area not populated with cells is pseudo-colored. B) Graph of average wound 
confluence for all wells for standard scratch wound assay. C) Representative images showing the 
migration of wildtype and Plk3-null MEFs using a novel woundless migration assay. D) Graph of 
average wound confluence for all image fields for woundless migration assay. 
 Regulation of Plk3 kinase activity by CIB1, a known mediator of integrin signaling, 
suggests that Plk3 might participate in regulation of cell attachment (29). Therefore, the capacity 
of Plk3-null and Plk3 proficient MEFs to attach to collagen-coated and fibronectin-coated culture 
plates was compared. The Plk3-null MEFs showed a slight but significant decrease in the 
percentage of cells attached to collagen-coated plates compared with their wildtype counterparts 
(Fig 13A); however, such a minor difference is unlikely to have biological relevance. Both 
wildtype and Plk3-null MEFs attached equally well to fibronectin-coated wells (Fig. 13B), and 
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both groups showed significantly more attachment to fibronectin-coated wells than their 
counterparts to collagen-coated wells.  Thus, Plk3 may play a minor role, if any, in the attachment 
of MEFs in cell-to-matrix adhesion. As metastasis is a hallmark of cancers and Plk3 is a suspected 
tumor suppressor (30-32), we asked whether loss of Plk3 would alter the invasiveness of MEFs. 
Cells were interrogated using a standard matrigel invasion assay. The Plk3-null MEFs were 
equally invasive as the wildtype cells (Fig. 13C), suggesting that loss of Plk3 neither facilitates 
nor impairs the invasive potential of these cells.  
 
Figure 13. The absence of Plk3 does not significantly alter cell attachment efficacy or invasion 
in MEFs. A&B) Graphs comparing the means of the average number of Plk3-null or wildtype 
MEFs attached per well to collagen IV and fibronectin-coated plates, respectively. C) Graphs 
comparing the average number of invasive Plk3-null or wildtype MEFs per well after 20 hours. 
 
 Absent any discernible phenotype associated with loss of Plk3 in mice or MEFs, we asked 
whether compensatory gene expression might provide an explanation. We therefore performed 
RNA-Seq on mRNA from wildtype and Plk3-null MEFs. Importantly, the low level of Plk3 mRNA 
in Plk3-null MEFs is most likely artifactual and likely due to misalignment of transcript belonging 
to some of the other Plks. This interpretation is supported by the total absence of Plk3 when the 
same cDNA library from Plk3-null MEFs was tested by qPCR.  Interestingly, the mRNA level of 
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Plk2 was significantly higher than that of all the other members of the Plk family (8-10 fold over 
Plk1 and Plk4) and about 30 fold higher than the level of Plk3 transcript in wildtype and MEFs 
(Fig. 14). Thus, since Plk2 is so highly expressed in both wildtype and Plk3-null MEFs, it is 
possible that Plk2 could compensate for the loss of Plk3 leading to the absence of phenotypes 
observed in our studies.  
 
Figure 14. Relative levels of mRNAs transcript for the Plk family. In the absence of a 
discernible phenotype in Plk3-null MEFs, RNA sequencing was performed to determine whether 
another Plk family member could potentially be compensating for loss of Plk3. The graph shows 
the standardized level of mRNA for each Polo-like kinase family member in MEFs and Gapdh as 
a control. 
 To address this hypothesis, we acquired a BALB/c strain of Plk2 knockout mice and 
attempted to breed the Plk2, Plk3 double knockout animals. The Plk2 knockout mice were 
generously provided from Dr. Jeffery Rosen at Baylor University in Waco, Texas, with the 
permission of the original creators at Perrigo Company plc (Ireland). Here, we are the first to 
demonstrate that Plk2, Plk3 double knockout mice are viable and do not present a clear phenotype. 
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We set-up three separate sets of crosses between the Plk2 and Plk3 mice. The first crosses, Plk2+/-
, Plk3+/- x Plk2+/-, Plk3+/- mice generated a total of 91 mice. Of these offspring, three pups were 
Plk2, Plk3 double knockout pups (Fig. 15A). To increase the probability of double-null offspring, 
Plk2+/-, Plk3+/- x Plk2+/-, Plk3-/- crosses were set-up and generated a total of 98 mice. Mendelian 
distribution of alleles predicts approximately 12 double-null mice, while the actual number of 
double-null offspring generated was 4 mice; significantly lower than predicted (Fig. 15B). The 
final cross, Plk2+/-, Plk3-/- x Plk2+/-, Plk3-/- mice generated a total of 18 mice. Based on the parental 
genotypes, a quarter of their offspring would be expected to Plk2/Plk3 double-null, however, this 
mating did not to generate a single double-null animal (Fig. 15C). In the second and third set of 
crosses, the number of double-null animals generated was significantly lower than the number of 
double-null mice expected. This outcome suggests that the combined loss of Plk2 and Plk3 may 
have a detrimental effect on embryonic development. In addition, two of seven double-null mice 
showed stunted growth rates with one dying of unknown causes just prior to one month old. 
Unfortunately, the body was cannibalized by his littermates, so a cause of death could not be 
determined. The other five double null offspring had no discernible phenotype. Importantly, this 
stunted growth phenotype also occurs seemingly at random in the Plk2-null only mice, both in 
publication and in Plk2-null mice we generated, suggesting it may be not be related to the 
combined loss of Plk2 and Plk3. This finding is complicated because it suggests that compensatory 
signaling between Plk2 and Plk3 maybe present but not absolutely required for fetal development 
or viability. Nonetheless, although the level of reciprocal compensation between the Plks remains 
a significant and outstanding question within the field, we have taken an important first step toward 
an answer and developed a potentially valuable model system.  
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C). 
 
Figure 15:  Plk2, Plk3 double knockout mice are viable although potentially at a lower than 
predicted ratio.  A.) Plk2+/-, Plk3+/- x Plk2+/-, Plk3+/- mouse crosses showing the expected versus 
actual numbers of offspring generated for each genotype (n = 91). B.) Plk2+/-, Plk3+/- x Plk2+/-, 
Plk3-/- mouse crosses showing the expected versus actual numbers of offspring generated for 
each genotype (n = 98). C.) Plk2+/-, Plk3-/- x Plk2+/-, Plk3-/- mouse crosses showing the expected 
versus actual numbers of offspring generated for each genotype (n = 18). 
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CHAPTER FIVE: 
Discussion 
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 The results of the investigation into a potential synthetic lethal relationship between p53 
and Plk3, while not entirely exhaustive, when combined with the available literature were 
sufficient to refute the hypothesis. The viability of p53, Plk3 double knockout mice demonstrated 
that a strict synthetic lethal relationship does not exist between the two genes, at least in mice.  On 
the other hand, the fact that the number of mice born homozygous null at both loci was significantly 
lower than expected based on Mendelian segregation of alleles suggests that the combined absence 
of both proteins may interfere with normal development. This is an area that deserves further 
attention and could yield new roles for both proteins in embryonic and/or fetal development.     
 Yet, p53 and Plk3 are primarily stress response proteins, so it was reasonable to infer that 
a synthetic lethal relationship could potentially be induced by challenging cells with DNA damage. 
Further, the elevated levels of endogenous double-stranded DNA breaks in double-null MAFs, as 
shown by staining for γH2AX foci, suggested that combined loss of Plk3 and p53 might sensitize 
cells to treatment with DNA damaging agents. For that reason, we switched to assaying cell death 
in a cell type known to be sensitive to radiation exposure, mouse thymocytes. Contrary to our 
hypothesis, the p53, Plk3 double knockout thymocytes were noticeably more resistant to radiation 
induced cell death than their wildtype counterparts. These data strongly suggests that the combined 
absence of p53 and Plk3 does not confer DNA damage-inducible synthetic lethality in this cell 
type.  
 Lastly, the prediction that the combined loss of p53 and Plk3 would result in ablation of 
the G/1 checkpoint was not supported by the flow cytometry data from the isogeneic HCT116 
cells. The p53-deficient HCT116 cells showed a near ablation of the G1/S checkpoint in response 
to even low-dose radiation, regardless of the presence or absence of Plk3 shRNA. These data imply 
that inhibition of Plk3 in wildtype p53-deficient cancers would not facilitate the accumulation of 
 59 
 
additional DNA damage through uncontrolled entry into S-phase. Moreover, re-entry into S-phase 
in these cells appears to be controlled by cell cycle arrest in the G2/M checkpoint. G2/M 
checkpoint arrest occurred regardless of the status of either p53 or Plk3, meaning the HCT116 are 
not dividing uncontrolled in the absence of both proteins. In aggregate, the data do not support the 
potential for a DNA damage induced synthetic lethal relationship between p53 and Plk3.  
 In addition to the findings discussed above, our decision to change directions was 
supported by the p53 and Plk literature. For instance, a 2009 study in the laboratory of Bert 
Vogelstein developed a panel of colorectal cancer cell lines in which each cell line was paired with 
an identical cell line except that its endogenous WT TP53 expression had been eliminated. The 
four sets of matched cell lines were exposed to ionizing radiation in order to define the effects of 
deletion or mutation of TP53 on gene expression profiles. Analysis of the transcriptomes revealed 
Plk1 to be one of only 35 genes whose expression showed at least a 2-fold increase in all of the 
TP53 deficient cell lines compared to their matched control. This result lead the authors to test the 
efficacy of Plk1 inhibition at killing TP53-deficient cell lines. This hypothesis was validated by 
demonstrating that treatment of stressed cells with Plk1 inhibitors lead to selective induction of 
apoptosis only in the TP53-deficient cell lines. This same study also demonstrated that Plk3 
expression was upregulated in response to ionizing radiation exposure only in the cell lines 
expressing WT TP53. These results are discussed here, as they have obvious implications for our 
hypothesis that should have given us greater pause at the conceptual stage of our project.  First, 
functional compensation for loss of p53 by Plk3 is less likely if transcription of Plk3 in response 
to DNA damage is primarily p53-mediated.  Second, Plk1 functions in direct opposition to Plk3 to 
promote cell cycle progression and Plk1 overexpression drives cancer cells to continuously divide. 
Elevated Plk1 levels in cancer cells lacking wildtype p53 would imply that Plk3 signaling for 
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checkpoint arrest is unlikely to be present and, if present, is being impaired and/or overruled by 
Plk1 signaling. Finally, selectively inhibiting Plk3 function in such cases might not be desirable, 
because it would presumably eliminate a cellular mechanism for Plk1 inhibition, an outcome 
shown to be desirable by this study. In this scenario, inhibition of Plk3 in p53-deficient tumors 
could potentially be detrimental to patient outcomes by empowering Plk1 to promote tumor 
growth. These points are discussed here to demonstrate that experiences from our first project, 
were not merely written off as bad luck and that they provided a valuable lesson for moving 
forward.  Namely, the importance of not choosing a project based on a narrow interpretation of the 
available scientific literature, as acknowledging these points would have guided our studies in a 
different direction. 
 Subsequently, we refocused our efforts on a project involving Plk3 with a higher 
probability of success. Preliminary data generated in our lab, particularly a standard scratch-wound 
assay, which showed impaired migration in Plk3-null MEFs was critical to our decision to pursue 
a role for Plk3 in the regulation of cytoskeletal architecture and cell motility. Additionally, a 
diverse set of studies cumulatively suggested a potential role for Plk3 in cytoskeletal regulation. 
Perturbation of microtubule integrity has been ascribed to dysregulated Plk3 (73,86), and Plk3 has 
been localized to centrosomes, particularly during cell division (78,87). Plk3 clearly co-
immunoprecipitates with CIB1, a protein linked to the inhibition of Plk3 activity (73,88). 
Furthermore, CIB1 has been reported to regulate microtubule organization in coordination with 
Plk3, and has been implicated as a regulator of the p21-activated kinases that contribute to 
cytoskeletal rearrangement and cell migration (89).  Further, adhesion of monocytes to a substrate 
increased levels of Plk3 mRNA, consistent with possible CIB1 involvement (88). Targeting Plk3 
with a shRNA in T47D cells also led to multinucleation, further suggesting that loss of Plk3 
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compromises microtubule architecture and cytokinesis (87). In aggregate, these studies reasonable 
suggested a role for Plk3 in the cytoskeletal regulation. 
 Our results, however, indicated that the absence of Plk3 in mouse embryo fibroblasts has 
little, if any, effect on cytoskeletal organization, cell adhesion, migration or invasion. The initial 
scratch wound assay, which attempted to replicate the preliminary scratch wound assay, gave us 
different but modestly encouraging results. While we did not see an ablation of directional cell 
movement as in the preliminary experiment, the delayed rate of migration in the Plk3 knockout 
MEFs suggested loss of Plk3 could impair cell motility. However, the experiment proved 
extremely difficult to reproduce and generating statistics would have required individual analysis 
of hundreds of images. By utilizing the IncuCyte Zoom, we were able to simultaneously conduct 
96 scratch wound assays and generate data on the rate of migration across all wells. Using this 
method, it quickly became clear that loss of Plk3 did not impair the ability of cells to migrate into 
a wound. The different results from the preliminary assay, our standard scratch assay, and our 
scratch wound assays using the IncuCyte left us somewhat uncertain which result was real. To this 
end, we collaborated with Dr. Ho’s lab to conduct the woundless migration assay. The data from 
this method also suggested that there was no difference in the rate of migration between wildtype 
and Plk3 knockout mice. When combined with the volume and quality of the data generated by 
the IncuCyte scratch wound assay, we now feel confident with a result showing no difference in 
migration in the absence of Plk3, at least in MEFs.  This finding was surprising given the numerous 
reports arguing in support of an association between Plk3 and elements of the cytoskeleton.   
 Although the literature predicts the involvement of Plk3 in the dynamics of cytoskeletal 
organization, adhesion, migration and invasion, in retrospect the use of mouse embryonic 
fibroblasts as a model system may have been overly optimistic.  The fact that mice lacking Plk3 
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have normal fecundity and display normal development over their lifetime, suggests that the 
complete absence of Plk3 alone has no overt deleterious effects on development or in vivo cellular 
effects. This proposition is supported by our RNA-seq data showing that the level of Plk3 mRNA 
is relatively low compared to the whole genome set. It is also possible that no altered phenotype 
was observed because Plk3 is solely a stress response kinase and MEFs were not subjected to an 
appropriate challenge, although the intent of the project was to identify functions for Plk3 outside 
of its roles in stress response signaling.  
 Nevertheless, the data provide insight into the functionality of Plk3, suggesting that its 
interactions with cytoskeletal components and CIB1 are not directly involved in regulation of cell 
morphology or motility. These findings further provide direction to future studies, allowing future 
research to focus on alternative possibilities when investigating a role for Plk3 in cytoskeletal 
regulation. For example, an important outstanding question is the consequences of Plk3 
phosphorylation on β-tubulin (54). One intriguing possibility is that Plk3 phosphorylates β-tubulin 
to regulate intracellular trafficking of itself and/or other proteins. This idea fits with the 
understanding of Plk3 localization as being tightly regulated during cell division. It is also 
consistent with the discrepancies in the literature over Plk3 subcellular localization. Plk3 has been 
reported to localize at the cell periphery, located outside the nuclear envelope, generalized to the 
nucleus, and specifically inside the nucleolus (90). Given the generally poor quality of Plk3 
antibodies, it is possible that some these reports are simply wrong, however, it also seems likely 
that Plk3 is actively shuttled to different cellular locations depending on unclear parameters. The 
localization of Plk3 to the cell periphery aligns nicely with the initial discovery of Plk3 as an early 
response gene following stimulation of serum-starved cells with fibroblast growth factor (FGF) 
(4,6). This localization also matches with CIB1 regulation of Plk3 because CIB1 is a myristoylated 
 63 
 
protein thought to be permanently attached to the cell membrane (91). It is possible that prior to 
stress exposure, Plk3 is localized to the cell membrane, whereupon challenge, it phosphorylates 
tubulin to mediate its own transportation to the nucleus. This proposition also aligns well with the 
putative nuclear localization sequence in Plk3 (55). In this manner, Plk3 could function as both an 
early response gene in the cytoplasm and facilitate cell cycle arrest and other functions in the 
nucleus.    
 The Plk2, Plk3 mouse work, while only recently begun, still generated a valuable result for 
our studies. The knowledge that Plk2, Plk3 double knockout mice are viable shows that 
compensation for Plk3 by Plk2 and vice versa is not strictly required at the organism level. Further, 
if the lab invested in generating sufficient numbers of Plk2 knockout mice and Plk2, Plk3 double 
knockout mice, we could determine if the delayed growth phenotype was occurring with higher 
penetrance in the double knockout animals. The results of such a study would illuminate whether 
compensatory signaling during development was likely to exist. If no difference in penetrance 
between the two genotypes was observed it would suggest that either other kinases are capable of 
compensating for the loss of both proteins, which is made less likely by the structural isolation of 
Plks, or that these two proteins do not possess essential functions in healthy, non-stressed animals. 
Additionally, in the future, cells and tissues derived from the double-null animals could be 
subjected to cytotoxic and/or genotoxic challenge to search for stress-induced functions and/or 
compensation between Plk2 and Plk3.    
 Over a quarter-century removed from the discovery of polo, a considerably amount is 
known about the structure, function, and disease-relevance of the Polo-like kinase family. In the 
past decade, Plk1 has been the most extensively studied of the Plks. For the most part, these 
studies were coupled with a translational focus, because continuous Plk1 expression is oncogenic 
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and a primary driver of cancer cell division (30,31,38,39). In contrast, Plk3 broadly opposes Plk1 
function, is a putative tumor suppressor, and appears to be downregulated in a significant subset 
of cancers (31). Investment improving our currently limited understanding of Plk3 regulation and 
function is essential if we want to understand how Plk3 downregulation affects cancers. The 
knowledge gained from these studies could ultimately aid in the development of or improve 
clinical efficacy of inhibitors for Plks.  
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